ADHD medication mortality is in the spotlight after a major systematic review found that people with attention-deficit hyperactivity disorder face a sharply higher risk of early death, while prescription treatment was associated with a roughly 25 per cent reduction in that risk.
The review, published in JAMA Network Open and reported by ScienceAlert, was led by researchers at University College London and the University of Liverpool. It pooled data from 19 cohort studies published between 2012 and 2025, covering close to 16 million participants across the United States, Canada, Sweden, Taiwan, the United Kingdom, Finland and Denmark.
The headline numbers are stark. Across the pooled observational studies, adults and children with an ADHD diagnosis had a 70 per cent higher rate of death from any cause than people without the diagnosis. The rate of death by suicide was 90 per cent higher, the rate of death from injuries, whether intentional or accidental, was 55 per cent higher, and the rate of death from natural causes was 27 per cent higher.
Some of the included studies followed participants for more than two decades, allowing the researchers to track mortality patterns across a substantial portion of the life course. ADHD affects about 5 per cent of children and 2.5 per cent of adults, making the findings relevant to millions of families.
Senior author Joshua Stott of UCL Psychology and Language Sciences said the team had previously found that people with ADHD have reduced life expectancies, and that the new work adds to understanding of what drives that concerning statistic. The excess risk covers not only suicide and injury but also deaths from natural causes, suggesting broad and wide-ranging health inequalities.
What the ADHD medication mortality review found
The promising signal on treatment came from three of the 19 studies that specifically tracked medication status. Among individuals diagnosed with ADHD, those who were prescribed ADHD medication exhibited an estimated 25 per cent reduction in all-cause mortality compared with untreated peers.
The study does not distinguish between the effects of different medications, though stimulants are the drugs most commonly prescribed for the condition. The researchers cautioned that the protective effect was drawn from a small subset of studies and needs further targeted investigation.
First author Lucy Corrigan of the University of Liverpool said the findings provide early evidence that medication may play an important role in supporting the health of people with ADHD, but that this is based on a small number of studies and further research is needed to clarify the link. Medication is just part of the story, she said, and many people with ADHD benefit from comprehensive, long-term treatment and support.
The mechanisms behind the excess risk are becoming clearer. Unintentional injury deaths, such as road deaths, may be linked to differences in attention, while deaths from natural causes may reflect elevated rates of cardiovascular disease, type 2 diabetes, metabolic syndrome and cancer.
Caveats behind the ADHD medication mortality link
The methods used are not intended to show cause and effect. The authors stress that the research cannot prove that ADHD causes these mortality rates, nor that ADHD medication caused the reduction in mortality. Observational studies can identify patterns, but they cannot rule out other explanations.
The authors also saw considerable variation between studies, which might reflect differences in gender balance, cultural attitudes, health care services in different countries and changes in ADHD diagnosis and management over the past decade.
Excess natural-cause mortality is frequently compounded by lifestyle risk behaviours, including tobacco, alcohol and substance use, as well as systemic barriers to health care engagement, difficulty scheduling appointments and reduced adherence to chronic disease regimens. People with ADHD also face more societal exclusion, disadvantage and stigma.
Despite the caveats, the researchers say the findings underline the importance of equitable access to evidence-based assessment and treatment. While ADHD diagnosis rates have risen in recent years, they may still lag behind actual prevalence, particularly for older age groups where mortality risk may be most pertinent.
The review is one of the most comprehensive syntheses to date on mortality among people with ADHD. Its message is twofold. The risks of leaving ADHD undiagnosed or untreated are substantial, and while medication is not a complete answer, the early evidence suggests it may play a meaningful role in helping people with ADHD live longer, healthier lives.